Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085065" target="_blank" >RIV/00023001:_____/24:00085065 - isvavai.cz</a>
Result on the web
<a href="https://academic.oup.com/eurheartj/article/45/37/3889/7738073" target="_blank" >https://academic.oup.com/eurheartj/article/45/37/3889/7738073</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/eurheartj/ehae534" target="_blank" >10.1093/eurheartj/ehae534</a>
Alternative languages
Result language
angličtina
Original language name
Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction
Original language description
Treatment with dapagliflozin for 24 weeksincreased plasma PYY levels, and the extent of this increase was correlated with weight loss, particularly adipose tissue loss, and favourablehaemodynamic effects during exercise. These data raise the possibilitythat SGLT2i-mediated increases in PYY may contribute to weight lossin obese HFpEF through increased satiety, with secondary haemodynamic benefits.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů